The world is in the midst of a mental health crisis as millions struggle to find accessible, effective treatments for depression, anxiety, and PTSD. These conditions drive a $44 billion global market for therapeutic interventions, yet the current pharmaceutical standard of care often creates complications and dependencies and falls short of its ultimate promise of reliably delivering a new level of well-being.

SoundSelf offers a scalable, non-drug solution that bypasses these limitations, making transformative mental health care both accessible and cost-effective. Positioned to capture a share of this rapidly growing market, SoundSelf combines digital innovation with clinically validated therapeutic impact.

New Technology, Ancient Technique

SoundSelf is a biofeedback system combining immersive technology and game design to amplify the effectiveness of traditional breath and vocal-toning meditation techniques. It is effective at producing states of wonder and oneness, which can have a rapid and transformative impact on mental health.

Breaking Through Regulatory Barriers in the Psychedelic Market at a Critical Juncture

Psychedelic interventions are rapidly gaining recognition for their potential to deliver life-changing results. However, these treatments face major accessibility barriers.

FDA Rejection of MDMA Therapy Creates Demand for Alternatives: The FDA's recent rejection of MDMA as a treatment has left care providers and investors scrambling for alternatives. Fortunately, SoundSelf offers psychedelic-like benefits without the need for drugs—bypassing regulatory delays and making transformative care accessible now.

Surging Demand in Ketamine Therapy: While the industry navigates regulatory obstacles, ketamine therapy remains a vital, accessible option. Following an independent study at Palm Beach Atlantic University, SoundSelf is now the only clinically validated digital tool for ketamine therapy, proven effective in preparation and integration.

With over 450 practitioners on the waitlist and ready to integrate this powerful tool into their treatment protocols, SoundSelf is ready to scale now, providing the essential preparation and integration infrastructure that will become increasingly critical as the ketamine market matures, and as other psychedelic therapies enter the market.

Clinical Testimonial from Cornerstone Psychiatric Care

"A lot of our patients actually have a hard time putting it into words. It's more the expressions on their faces, the sigh of relief afterward.

SoundSelf takes ketamine to the next level. It helps our patients explore their own tools so that when they're not in the clinic, they are able to reduce their anxiety and get back into the state they were in during the session.

From a business perspective, it allows us to have more touchpoints with our patients. With SoundSelf, we can bring the patient into the clinic on non-treatment days, spend that time with them, assess them, help them, and listen to them."

- Jessica Shepley, Psychiatric & Family Nurse Practitioner

The Product is Modular and Upgradable

SoundSelf Outperforms Competitors for Engagement and Transformative Impact.

In 2023, SoundSelf ran a stealth beta with 80 paying practitioners. Data and insights collected from the beta validated product-market fit in the ketamine sector and demonstrated early revenue potential.

With over 450 clinical practitioners on the waitlist and 14,000 B2C downloads from its previous consumer release, SoundSelf is now primed to scale, delivering innovative, effective care for patients in clinics worldwide.

Three Studies have Scientifically Validated Years of Treatment Results. The Results are Groundbreaking.

Research on brain states during SoundSelf shows that it non-invasively activates psychedelic-like states without a drug, and that regular long-term use carries identical therapeutic benefits to psychedelic-assisted therapy.

EEG Study Shows:

• An increase in gamma waves across many regions of the brain.
• A decrease of activity in brain regions associated with the Default Mode Network (mind wandering and agitation).
• These are the signature indicators of deep meditation and profound insight.

Study of Long-Term Mental Health Changes Shows:

Ketamine Adjunct Study Shows:

Participants with depression and anxiety using a ketamine + SoundSelf protocol saw major reductions in their symptoms: depression scores dropped by over 30%, anxiety scores by nearly 25%, and stress levels decreased significantly.

Additionally, users reported feeling more mindful and aware. These findings confirm what we have been seeing in the field: SoundSelf is a powerful tool to enhance ketamine treatment outcomes for those struggling with depression and anxiety.

Independent university studies are proving that SoundSelf outperforms pharmaceuticals for many mental health disorders.

Funding

Capital Raised and Current Funding

SoundSelf has raised $2 million to date. This has funded groundbreaking R&D, a robust clinical beta, and the establishment of partnerships with over 80 practices. With a rapidly growing waitlist, SoundSelf is ready to build on this momentum, expanding its clinical reach and operational capabilities.

Use of Funds

This community round is strategically timed ahead of our upcoming Seed round, which already has $1 million committed by a European neurotech VC.

The objective is simple: build sales revenue starting with our 450-practice waitlist, and establish SoundSelf as a staple of the ketamine therapy sector.

Your investment will enable SoundSelf to:

• Hire a Head of Growth
• Fund a Phase II Research Study that shows SoundSelf's efficacy in anxiety and depression disorders
• Sponsor ketamine-focused events, standardizing SoundSelf as an essential tool for ketamine therapy.
• Educate clinics on best practices for preparation and integration

Projections

Ketamine is just the beginning. SoundSelf is preparing for an FDA bid that will help it provide economical and transformative solutions to the enormous Depression, Anxiety, and PTSD markets.

(projections not guaranteed)

Exit Plan

Digital Therapeutics (DTx) are a growing sector of increasing importance to mainstream medicine, especially in the areas of pain management and mental health. With the FDA's endorsement of digital-adjunct strategies for mental health and the associated cost-benefits for consumers, drug developers are already making DTx acquisitions. We expect the marketplace for acquisitions to mature in the late 2020s. Prior to that, we are likely to see more DTx roll-ups for IPO or sale.

Either way, the technological and data infrastructure we have built to make clinical distribution possible is scalable and generalizable. Our plan is to develop SoundSelf from being a standalone solution to become the immersive DTx distribution platform for mental health. It will be a valuable acquisition target for any partner who needs clinic access and precision AI-driven treatments.

About the Perks

Can I have SoundSelf for my home?

This Wefunder is the only way for private individuals to get a SoundSelf unit for their personal use. Invest $5,000 or more to take advantage of this unique opportunity while it's still available.

Can SoundSelf be white-labeled?

Yes, whitelabeling is exclusively available through this campaign. Choose the "Transform" perk, and we will customize the SoundSelf experience for your needs. With our audio lead's help, you (or a VO artist of your choosing) will record branded and targeted therapeutic content for your practice to be integrated into a white-labeled version of the technology. We'll even fly out to your office anywhere in the continental US to train your staff and make sure you get the most out of your special offering.

Get in Early—Profit from the Future of Mental Health

By investing in SoundSelf, you’re claiming your piece of a platform that is scaling to disrupt an antiquated mental health system. This is more than an investment in technology; it’s your chance to help redefine mental health care at a definitive turning point.

We look forward to working together with you to bring a genuine and transformative solution to a market that is in desperate need of real change.